Bactiguard changes strategy for Russia and India

Bactiguard has terminated the distribution agreement for Russia and evaluates an
alternative sales strategy for India. In connection with the above, the company
has decided to make reservations in the interim results for the first quarter of
2015 for doubtful receivables, with a negative effect on results of
approximately MSEK 24.
During the first quarter of 2015, Bactiguard has reviewed and evaluated market
conditions in Russia. Given the economic/political developments in the country,
Bactiguard has decided to focus its marketing and sales efforts on other growth
markets with greater potential.

Consequently, Bactiguard has used its right to terminate the agreement with its
Russian distributor. No product deliveries have been made to Russia so far and
there are no outstanding commitments to deliver any products.
India remains an important growth market for Bactiguard. The cooperation with
Cadila Pharmaceuticals Ltd which was initiated in 2012 has, however, not
provided the regulatory and market related benefits expected at the time.
Therefore, Bactiguard is evaluating an alternative sales strategy, which paves
the way for market launch and initiation of sales in 2015, as planned.
Preparations for the launch and clinical studies are well under way.
As a result of the above changes in strategy, Bactiguard has decided to make
reservations in the interim results for the first quarter of 2015 for doubtful
receivables, with a negative effect on results of approximately MSEK 24. The
reason being that the counterparties’ willingness to pay is deemed questionable.
The reservations have no effect on the company’s cash position.

This is information that Bactiguard Holding AB (publ) is required to publish in
compliance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on 1
April 2015, at 08.00.
For further information, please contact:

Cecilia Edström, Acting Director of Sales, Marketing and Communications
cecilia.edstrom@bactiguard.com
mobile: 46 722 262 328
About Bactiguard
Bactiguard is a Swedish medtech company with a mission of preventing healthcare
associated infections, reducing the use of antibiotics and saving lives by
developing and supplying infection prevention solutions for the healthcare
industry. The company’s patented coating prevents healthcare associated
infections by reducing bacterial adhesion and growth on medical devices.
Bactiguard®-coated urinary catheters are market leading in the US and Japan, and
in recent years the company has developed its own product portfolio of catheters
for the urinary and respiratory tract and the blood stream. Bactiguard is
currently in a strong expansion phase, focused on new markets in the Europe,
Middle East, Asia, Latin America and Southern Africa. The company has market
presence in some 50 countries and has about 60 employees. Its headquarters is
located in Stockholm and production facilities in Sweden and Malaysia.
Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at
www.bactiguard.com